News - OXB - Page 15

Oxford BioMedica Notes Encouraging Results of the Investigator Led Phase I/II clinical trial of MVA-5T4 Immunotherapy (TroVax®) and Low Dose Cyclophosphamide in Patients with Advanced Colorectal Cancer

~ Both Cyclophosphamide and TroVax® independently shown to induce highly beneficial anti-tumour immune responses, resulting in significantly prolonged survival of advanced colorectal cancer patients Oxford, UK – 24 February 2017: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today notes the results from a… Read More

Oxford BioMedica Notes Findings Reported by Novartis on CTL-019 at 58th American Society of Hematology Annual Meeting

Oxford, UK & London, UK– 5 December 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes the findings reported by Novartis on their clinical trial (ELIANA) evaluating the efficacy and safety of CTL019, an investigational chimeric antigen receptor T cell… Read More

Oxford BioMedica Announces a Strategic Alliance with Orchard Therapeutics

Oxford, UK & London, UK– 29 November 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces it has entered into a strategic alliance with Orchard Therapeutics (“Orchard”), a biotechnology company dedicated to bringing transformative ex-vivo stem cell based gene therapies… Read More

Oxford BioMedica Announces Publication of Pioneering RetinoStat® (Oxford Biomedica-201) Phase I Study Data in the Journal, Human Gene Therapy

— RetinoStat® met its primary endpoint, demonstrating favourable safety and tolerability profiles Oxford, UK – 10 October 2016: Oxford BioMedica plc (LSE:OXB)… Read More

Oxford BioMedica Result of General Meeting and Directors Dealing

London, UK – 29 September 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, announces, in accordance with Listing Rule 9.6.18, that all resolutions proposed at its General Meeting, held… Read More

Interim Results for the six months ended 30 June 2016

Oxford BioMedica plc Interim Results for the six months ended 30 June 2016 Oxford, UK – 13 September 2016: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy group, today… Read More

Oxford BioMedica Announces MHRA GMP Manufacturing Approvals and Completion of Expansion Phase

– World-class centre for lentiviral gene therapy bioprocessing and process development approved and fully operational – Capital expenditure and expansion of Group’s facilities now… Read More

Oxford BioMedica to Present at the Jefferies 2016 Healthcare Conference, New York

Oxford, UK – 6 June 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces that Tim Watts, Chief Financial Officer, will be presenting at the Jefferies 2016 Healthcare… Read More

Press Releases

News from the year: /2013

Oxford BioMedica Notes Encouraging Results of the Investigator Led Phase I/II clinical trial of MVA-5T4 Immunotherapy (TroVax®) and Low Dose Cyclophosphamide in Patients with Advanced Colorectal Cancer

Oxford BioMedica Notes Findings Reported by Novartis on CTL-019 at 58th American Society of Hematology Annual Meeting

Oxford BioMedica Announces a Strategic Alliance with Orchard Therapeutics

Oxford BioMedica Announces Publication of Pioneering RetinoStat® (Oxford Biomedica-201) Phase I Study Data in the Journal, Human Gene Therapy

Oxford BioMedica Result of General Meeting and Directors Dealing

Interim Results for the six months ended 30 June 2016

Oxford BioMedica Announces MHRA GMP Manufacturing Approvals and Completion of Expansion Phase

Oxford BioMedica to Present at the Jefferies 2016 Healthcare Conference, New York

Establishment of a New Non-Exclusive LentiVector® Licence with MolMed

Oxford BioMedica and Green Cross LabCell form a Partnership to Develop Gene-modified NK Cell Therapeutics in cancer

Oxford BioMedica Appoints Corporate Broker

Oxford BioMedica Board Change